[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
|
[2] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
|
[3] |
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis[J]. PLoS Med, 2014, 11(4):e1001624.
|
[4] |
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
|
[5] |
Trevisan França de Lima L, Broszczak D, Zhang X, et al. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2):188451.
|
[6] |
Lu CY, Chen SY, Peng HL, et al. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(4):6406-6418.
|
[7] |
Cai Z, Chen G, Zeng Y, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(17):5284-5294.
|
[8] |
Huang Z, Hua D, Hu Y, et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma[J]. Pathol Oncol Res, 2012, 18(2):271-276.
|
[9] |
Kotoh Y, Suehiro Y, Saeki I, et al. Novel liquid biopsy test based on a sensitive methylated SEPT9 assay for diagnosing hepatocellular carcinoma[J]. Hepatol Commun, 2020, 4(3):461-470.
|
[10] |
Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J]. Nat Commun, 2020, 11(1):3475.
|
[11] |
Feng S, Ding Z, Wang J, et al. Investigation of plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses[J]. Cancer Med, 2020, 9(14):5075-5085.
|
[12] |
Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12):2195-2205.
|
[13] |
Zhang Z, Chen P, Xie H, et al. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis[J]. Cancer Med, 2020, 9(4):1349-1364.
|
[14] |
Zhang J, Yuan Y, Gao S, et al. Diagnostic performance of circulating cell-free DNA for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Biomark Med, 2021, 15(3):219-239.
|
[15] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
[16] |
Wong IH, Lo YM, Yeo W, et al. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients[J]. Clin Cancer Res, 2000, 6(9):3516-3521.
|
[17] |
Wong IH, Zhang J, Lai PB, et al. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients[J]. Clin Cancer Res, 2003, 9(3):1047-1052.
|
[18] |
罗速, 张逢春, 刘成柏, 等. 血浆p16基因甲基化在原发性肝细胞癌诊断中的作用[J]. 吉林大学学报(理学版), 2004, 42(2):298-301.
|
[19] |
陈龙邦,林勍,唐永明,等. 原发性肝癌患者血清p16和DAPK基因启动子甲基化的研究[J]. 肿瘤防治研究, 2006, 33(3):175-177.
|
[20] |
Yeo W, Wong N, Wong WL, et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma[J]. Liver Int, 2005, 25(2):266-272.
|
[21] |
Ren N, Qin LX, Tu H, et al. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2006, 132(6):399-407.
|
[22] |
Hu L, Chen G, Yu H, et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(1):423-432.
|
[23] |
纪宗淑. 肝细胞癌患者血浆FHIT和SLIT2基因启动子甲基化的检测及意义[D]. 合肥:安徽医科大学, 2010.
|
[24 |
Chen H, Sun LY, Zheng HQ, et al. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Pathology, 2012, 44(4):318-324.
|
[25] |
张晔, 杨斌, 王毅军, 等. 肝癌血浆游离DNA甲基化谱检测及临床意义[J]. 中国肿瘤临床, 2013, 40(23):1436-1440.
|
[26] |
Ji XF, Fan YC, Gao S, et al. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(16):4723-4729.
|
[27] |
王哲, 吕岩. 肝癌中血浆DNA甲基化检出与DNMT 1mRNA表达情况[J]. 中国公共卫生, 2014, 30(9):1233-1234.
|
[28] |
Dong X, He H, Zhang W, et al. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection [J]. Diagn Pathol, 2015(10):133.
|
[29] |
冉贵萍, 黄海, 杨国珍, 等. 肝细胞癌患者血浆循环DNA的定量分析及临床意义[J]. 中国实验诊断学, 2015, 19(6):918-921.
|
[30] |
董晓刚, 郭文佳, 丁伟. p16、RASSF1A在肝细胞性肝癌患者肿瘤组织及血浆中异常甲基化的检测及临床意义[J]. 中国医药生物技术, 2016, 11(3):252-258.
|
[31] |
Dong X, Hou Q, Chen Y, et al. Diagnostic value of the methylation of multiple gene promoters in serum in hepatitis B virus-related hepatocellular carcinoma[J]. Dis Markers, 2017:2929381.
|
[32] |
Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11):1155-1161.
|
[33] |
Wei L, Huang Y, Zhao R, et al. Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases[J]. Clin Exp Med, 2018, 18(1):79-87.
|
[34] |
Yan L, Chen Y, Zhou J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma[J]. Int J Infect Dis, 2018(67):92-97.
|
[35] |
Xiong Y, Xie CR, Zhang S, et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma[J]. Cancer Manag Res, 2019(11):5745-5756.
|
[36] |
Tao K, Bian Z, Zhang Q, et al. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma[J]. EBioMedicine, 2020(56):102811.
|
[37] |
阎其均, 翁羽, 朱付英. 外周血CTCs、cfDNA联合检测在肝癌早期筛查中的应用价值分析[J]. 临床输血与检验, 2020, 22(4):429-433.
|
[38] |
Cai Z, Zhang J, He Y, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma[J]. ESMO Open, 2021, 6(1):100021.
|
[39] |
Li Y, Zheng Y, Wu L, et al. Current status of ctDNA in precision oncology for hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2021, 40(1):140.
|
[40] |
Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14(9):985-990.
|
[41] |
Song T, Li L, Wu S, et al. Peripheral blood genetic biomarkers for the early diagnosis of hepatocellular carcinoma[J]. Front Oncol, 2021(11):583714.
|
[42] |
Huang ZH, Hu Y, Hua D, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma[J]. Exp Mol Pathol, 2011, 91(3):702-707.
|